x

Support HDYO

HDYO is the only organization who focus solely on supporting young people impacted by HD around the world. Will you help us?

Donate
x
<span class="translation_missing" title="translation missing: en.hdyo.land.loading">Loading</span>
X
Home Language and Accessibility What is HD? New to HD? Find Resources Research Ask for Help About HDYO News Videos PDF Resources Join Mailing List Kids Teens Young Adults Parents and Family JoHD Friends Professionals DONATE! Privacy Contact Us

HD Clinical Trials and Studies

May 09, 2022

Huntington's Disease Youth Organization

HDYO has more information about HD available for young people, parents and professionals on our site:

www.hdyo.org

Where to Find Trials

HD TrialFinder is a clinical trials matching service: a way for individuals with Huntington’s disease, caregivers, healthy volunteers, and physicians to connect with current research studies. It includes an easy-to-use website and free call center staffed by trained HD clinical trial navigators. People with HD, care partners, and healthy volunteers are all needed today to participate in different aspects of HD research.

Visit HDSA TrialFinder Visit EHA TrialFinder

ClinicalTrials.gov is a website that lists research studies from around the world. This site can be challenging for the community to navigate if they don't have a scientific background. We suggest starting with the different TrialFinder sites first or review the resources below.

Visit clinicaltrials.gov

Summary of Current HD Research

Research into Huntington’s disease is an incredibly active field. This page summarises some of the major research studies currently underway that pertain to young people that HDYO serve. We’ve split the studies up into ‘observational’ and ‘interventional’ research. Observational research collects information about participants without interfering. This is very important to learn about a disease, find out how it usually progresses and discover measures like biomarkers that can be used for interventional research. Interventional research tests treatments for a disease, an important step in developing new drugs. For a simple explanation of the drug development process, see our video here.

This list will be updated as new information is made available. If you are involved in a HD research project not listed and would like it featured on this page, please get in touch by emailing rebecca@hdyo.org.

Observational Research

HDYO Survey Series

Who runs this study? Huntington's Disease Youth Organization

What’s its current status? Active.

Where is it running? Internationally.

Who’s potentially eligible? HD community members at least 18 years and older.

What are they investigating? HDYO is hosting a series of surveys to better understand behavior, stigmas, awareness and education around several areas of individuals impacted by Huntington's disease.

Find Out More

ChANGE HD

Who runs this study? The University of Iowa

What’s its current status? Active and recruiting.

Where is it running? United States.

Who’s potentially eligible? Young people aged 6 to 30 who are at risk for HD.

What are they investigating? ChANGE HD is a brain imaging study which will help explain how the gene responsible for HD affects brain development, and hopefully find a way to identify the best time for gene therapy during development.

Find Out More

Enroll-HD

Who runs this study? The CHDI Foundation

What’s its current status? Active and recruiting.

Where is it running? Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, New Zealand, Poland, Portugal, Russia, Spain, Switzerland, United Kingdom, United States.

Who’s potentially eligible? Anyone from a HD family, aged 18+, and children under 18 with a diagnosis of juvenile HD.

What are they investigating? Enroll-HD was launched in 2012 and has over 20,000 active participants. The goals of Enroll-HD include to better understand HD, to improve the design of clinical trials and to improve clinical care for HD patients. Participants visit their local study site annually to undergo assessments and give biospecimens.

Find Out More

FOCUS Online

Who runs this study? The CHDI Foundation

What’s its current status? Active

Where is it running? International and online

Who’s potentially eligible? Individuals who are gene positive for HD, 18 or older, and can speak English

What are they investigating? The purpose of the Study is to determine whether the FuRST 2.0 Scale can reliably and accurately capture information about the functional abilities of people with HD.

Find Out More

HDClarity

Who runs this study? University College London and the CHDI Foundation

What’s its current status? Active and recruiting.

Where is it running? Canada, Germany, Italy, Poland, Spain, United Kingdom, United States.

Who’s potentially eligible? Adults aged from 21 to 75, who fall under one of the following categories: healthy control, early pre-manifest, late pre-manifest, early manifest, moderate manifest, late manifest.

What are they investigating? HDClarity is a study designed to collect cerebrospinal fluid, the fluid that surrounds the brain and spinal cord. The samples and information collected will be used to study HD, including identifying and evaluating biomarkers, which may help researchers better understand the disease. In the future, these biomarkers could be used to help design clinical trials of new treatments.

Find Out More

HD-JUNIOR

Who runs this study? Leiden University Medical Center

What’s its current status? Active and recruiting.

Where is it running? The Netherlands.

Who’s potentially eligible? People in the Netherlands who developed HD symptoms before the age of 21.

What are they investigating? HD-JUNIOR is a national registry for patients with JoHD. They will collect medical information from participants' doctors and contact information so they can get in touch about future research opportunities. There is also an optional questionnaire that the participant or caretaker can fill in.

Find Out More

HD-YAS 1.0

Who runs this study? University College London Huntington’s Disease Centre

What’s its current status? Completed

Where is it running? UK

Who’s potentially eligible? Adults between the ages of 18 and 40 years old who are at-risk and premanifest (show no clinical symptoms of HD), including those who carry the HD gene or those who do not

What are they investigating? HD-YAS 1.0 studied a cohort of young adult HD gene expansion carriers decades before expected symptom onset to characterize the very earliest signs of disease-related brain changes and identify whether there is any identifiable early functional impairment. HD-YAS 1.0 showed that, although function was completely normal, there was some evidence of subtle early changes in gene carriers decades from developing the disease.

HD-YAS 2.0

Who runs this study? University College London Huntington’s Disease Centre

What’s its current status? Active

Where is it running? UK

Who’s potentially eligible? Adults between the ages of 18 and 40 years old who are at-risk and premanifest (show no clinical symptoms of HD), including those who carry the HD gene or those who do not

What are they investigating? The purpose of HD-YAS 2.0 is to determine whether there is any change over time in adults ages of 18-40 years old who are premanifest (show no clinical symptoms of HD) at enrollment in the study. The 131 participants who took part in HD-YAS 1.0 are being invited back to undergo similar assessments so we can look at what has changed. In addition, new participants are also being included to account for participants from the first study who may not want to participate again. This will help us to guide the use of any potential future treatments, so that they can be given at the earliest and most effective time in order to prevent or treat HD disease progression.

JOIN-HD

Who runs this study? HDYO

What’s its current status? Active and recruiting.

Where is it running? Worldwide.

Who’s potentially eligible? People with symptoms consistent with JoHD, caregivers of someone with symptoms of JoHD and previous caregivers of someone who had JoHD.

What are they investigating? JOIN-HD is an international registry where participants self-enrol and answer questionnaires online. The project aims to create a global community of families impacted by JoHD, to increase knowledge of this disease, and to facilitate future research.

Find Out More

Kids-JHD

Who runs this study? The University of Iowa

What’s its current status? Active and recruiting.

Where is it running? United States.

Who’s potentially eligible? Young people aged 4 to 30 years old with a diagnosis of JoHD.

What are they investigating? This study is trying to identify and measure common symptoms and developmental patterns that might be happening in JoHD.

Find Out More

MyHD Story

Who runs this study? The Huntington Study Group

What’s its current status? Active and recruiting.

Where is it running? United States with hopes of including international after pilot study is complete.

Who’s potentially eligible? * Adults age 18 years and older * Willing and able to provide informed consent electronically. * Individuals answering as a participant must self-report they have been diagnosed with HD by a doctor. * Ability to answer online questions or direct someone else to enter answers for them. * Ability to ambulate independently and take care of some of his or her personal needs. * Ability to read and understand English. * Willing to create a unique identifier based on personal demographic information. * Residing in the United States or its territories * Owning or having access to an electronic device (laptop, smartphone, or computer) and secure internet connectivity

What are they investigating? This study will help to understand how Huntington disease (HD) affects patients, care partners, and those at genetic risk for HD.

Find Out More

PREVENT-HD

Who runs this study? University of Wisconsin, Madison

What’s its current status? Active and recruiting.

Where is it running? United States.

Who’s potentially eligible? Adults from HD families who carry or do not carry the HD gene, people who have recently been diagnosed with HD and are in the very early stages of the disease, and people who are gene-positive, but are not currently showing any symptoms.

What are they investigating? This study aims to build a case for testing treatments much earlier in people at risk for HD. Starting treatment sooner may help delay the start of symptoms or slow down the progression of the disease. This study wants to plan for future clinical trials by finding and tracking subtle but measurable changes in behaviour, cognition, and emotional responses that occur before the more visible HD symptoms appear.

Find Out More

SHIELD HD

Who runs this study? Triplet Therapeutics

What’s its current status? Active, not currently recruiting.

Where is it running? Canada, France, Germany, United Kingdom, United States.

Who’s potentially eligible? Adults aged 18 to 63 with pre-manifest or early manifest HD.

What are they investigating? SHIELD HD is an international study to assess the natural history of HD and its biomarkers associated with modulation of the number of CAG repeats in the mutant huntingtin gene. The results of this study will inform assessments for a future interventional trial.

Find Out More

Interventional Research

Phase I study of ER2001 in Early HD

Who runs this study? ExoRNA Bioscience

What’s its current status? Active and recruiting.

Where is it running? China

Who’s potentially eligible? Adults between the ages of 25 and 55 with early manifest HD

What are they investigating? This clinical trial will assess the safety, tolerability, and pharmacokinetics of increasing doses of intravenously administered ER2001 in patients with early manifest HD. The study is expected to enroll 15 participants and run in Guangdong between April 2023 and October 2024.

Find Out More

DIMENSION

Who runs this study? Sage Therapeutics

What’s its current status? Active and recruiting.

Where is it running? United States.

Who’s potentially eligible? Adults aged 25 to 65 with pre-manifest or early manifest HD.

What are they investigating? This phase II trial will investigate the safety of the oral drug SAGE-718 and its effect on cognitive symptoms in participants with pre-manifest or early manifest HD.

Find Out More

KINECT-HD

Who runs this study? Neurocrine Biosciences and the Huntington Study Group

What’s its current status? Completed

Where is it running? Canada and United States.

Who’s potentially eligible? Adults aged 18 to 75 with a diagnosis of motor manifest HD.

What are they investigating? KINECT-HD conducted a Phase 3, randomized, double-blind, placebo-controlled study to investigate valbenazine (whose trade name is INGREZZA®) for the treatment of chorea in HD. Results demonstrated improvements chorea severity, compared to placebo and recently supported the ability of the U.S. Food and Drug Administration (FDA) to approved INGREZZA® (valbenazine) capsules for the treatment of adults with chorea associated with HD.

Find Out More

KINECT-HD2

Who runs this study? Neurocrine Biosciences and the Huntington Study Group

What’s its current status? Active and recruiting.

Where is it running? Canada and United States.

Who’s potentially eligible? Adults aged 18 to 75 with a diagnosis of motor manifest HD.

What are they investigating? KINECT-HD2 is an open-label rollover study of the previous trial KINECT-HD. This trial is investigating Valbenazine (whose trade name is INGREZZA®) for the treatment of chorea in HD. Initial results from combing KINECT-HD with current KINECT-HD2 patients recently supported the ability of the U.S. Food and Drug Administration (FDA) to approved INGREZZA® capsules for the treatment of adults with chorea associated with HD.

Find Out More

Phase I/II study of AMT-130 in HD

Who runs this study? uniQure

What’s its current status? Active and recruiting.

Where is it running? United States and Poland.

Who’s potentially eligible? Adults between the ages of 25 and 65 with early manifest HD.

What are they investigating? In this trial, uniQure are investigating low and high doses of their drug AMT-130 – a one-time gene therapy candidate administered by neurosurgical procedure, designed to silence the huntingtin gene. This 5-year trial will evaluate the safety and potential impact of AMT-130 on disease progression. Enrolment has been completed for the first two patient cohorts in the US. A third patient cohort is planned for the US to explore an improved administration procedure. An open-label arm of the study remains open to recruitment in Europe. Administration of high dose AMT-130 has been postponed due to recent suspected unexpected severe adverse reactions.

Find Out More

Phase I/II study of BV-101 in HD

Who runs this study? AskBio

What’s its current status? Not yet recruiting.

Where is it running? Expected to begin in France.

Who’s potentially eligible? Not yet known.

What are they investigating? The BV-101 clinical trial will assess the safety, tolerability, and preliminary efficacy of BV-101 in adults with early-stage HD. The trial will include 12-18 participants and is expected to begin in Paris in Q4, 2022. BV-101 is a gene therapy treatment, aiming to restore cholesterol metabolism, reduce mutant huntingtin and improve neuronal function.

Find Out More

Phase II Study of ANX005 in HD

Who runs this study? Annexon

What’s its current status? Completed.

Where is it running? United States.

Who’s potentially eligible? Adults aged 18 and over with, or at risk for, manifest HD.

What are they investigating? This is an open-label trial of the intravenous drug ANX005. ANX005 is an antibody designed to block an initiator of the immune response, which is known to contribute towards the neurodegeneration seen in HD. Results from this trial showed ANX005 was successful in targeting the complement system. In a subgroup of participants, it appeared the progression of symptoms was slowed, suggesting a sub-population of people with HD might benefit from treatment with ANX005. Annexon will likely conduct a larger trial to confirm these results.

Find Out More

Phase II Study of SOM3355 in Huntington's Disease Chorea

Who runs this study? SOM Innovation Biotech SA

What’s its current status? Active and recruiting.

Where is it running? Spain (more countries expected to be added soon).

Who’s potentially eligible? Individuals over the age of 21 diagnosed with Huntington's Disease and suffering with choreic movements.

What are they investigating? This trial is assessing the efficacy and safety of SOM3355 in patients suffering from Huntington's Disease with choreic movements. SOM3355 is an oral antihypertensive drug which has been used for years, and is now being tested to treat chorea in HD.

Find Out More

Generation HD2

Who runs this study? Roche

What’s its current status? Active and Recruiting

Where is it running? Opened in North America, Europe, South America and Oceania.

Who’s potentially eligible? People aged 25 to 50 with prodromal (very early subtle signs of HD) or early manifest HD.

What are they investigating? This study evaluates the safety, biomarkers and efficacy trends of different dose levels of investigational drug tominersen in people aged 25 to 50 with prodromal (very early subtle signs of HD) or early manifest HD.

Find Out More

PIVOT-HD

Who runs this study? PTC Therapeutics

What’s its current status? Active and recruiting.

Where is it running? Germany, France, Netherland, & UK.

Who’s eligible? Adults ages 25 and over with a CAG repeat between 42 and 50, with no functional or movement symptoms of HD.

What are they investigating? PTC are investigating their drug PTC518, taken orally, which has been designed to reduce the production of the mutated huntingtin protein. PTC518 has been tested in a Phase I trial in healthy volunteers. PIVOT-HD is a Phase II trial aiming to confirm dose-dependent lowering of huntingtin protein and gain insight to biomarker data that could provide meaningful evidence of treatment effect.

Find Out More

PROOF-HD

Who runs this study? Prilenia

What’s its current status? Completed; Analyzing Data

Where was it running? Austria, Canada, Czech Republic, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom, United States.

Who was potentially eligible? Adults aged 25 and over with early manifest HD.

What are they investigating? PROOF-HD is a Phase III trial to evaluate the efficacy and safety of the drug pridopidine on functional capacity in adults with early manifest HD. Pridopidine is a small molecule drug thought to target a protein called the sigma-1 receptor. Taken orally, it is hoped pridopidine will have beneficial effects on neuronal cells. Preliminary analysis showed the study did not find a significant effect on change in functional capacity when looking across all study participants (the primary endpoint). However, there was evidence of a potential benefit in the subset of patients that were not taking neuroleptics (e.g., antipsychotics) or chorea medications. Additionally, there were other potential benefits shown on secondary endpoints capturing motor scores. Pridopidine was well-tolerated with no serious treatment-related adverse events.

Read Community Letter About Initial Analysis

SELECT-HD

Who runs this study? Wave Life Sciences

What’s its current status? Active and recruiting.

Where is it running? Australia, Canada, Denmark, France, Germany, Italy, Poland, Spain, United Kingdom

Who’s potentially eligible? Adults aged 25 to 60 years with HD.

What are they investigating? This Phase Ib/IIa trial is investigating the safety and tolerability of WVE-003 in people with HD. WVE-003 is a drug designed to lower the toxic form of the huntingtin protein, delivered intrathecally (into the CSF through the spine). WVE-003 targets a specific genetic signature, which not every person with HD has, so if successful this drug would only be able to treat a subset of people with HD.

Find Out More

SURVEYOR

Who runs this study? Sage Therapeutics

What’s its current status? Active and recruiting.

Where is it running? United States

Who’s potentially eligible? Adults aged 25 to 65 with pre or early manifest HD and healthy controls.

What are they investigating? This phase II trial will investigate baseline cognitive performance difference between participants with early HD and healthy participants and the effect of SAGE-718 on cognitive performance and functioning in participants with HD.

Find Out More

VIBRANT-HD

Who runs this study? Novartis

What’s its current status? Novartis recently announced they have stopped the development of Branaplam in Huntington's disease.

Read Community Letter

Our content is split into different groups. Choose the group that best describes your needs for more information on HD.

Kids Teens Young Adults Parents and Family JoHD Friends Professionals